A patient with advanced hepatocellular carcinoma (liver cancer) who participated in the Phase II trials of namodenoson from Israel’s Can-Fite (see here previously) had an extremely good response. His liver function returned to normal, and he is looking forward to … Continue reading →

I reported previously (see here) on the Namodenoson (CF102) liver cancer treatment from Israel’s Can-Fite. After Phase 2 testing, a supply of CF102 has been manufactured for “compassionate use” on critically ill patients at Rabin Medical Center in Petah Tikva. … Continue reading →

In advance of Phase 2 trials, preclinical data showed the potential efficacy of Namodenoson (CF102) from Israel’s Can-Fite (see Jan 2012).  It inhibited the growth and proliferation of liver fibrosis cells, supporting its potential ability to combat non-alcoholic fatty liver … Continue reading →

Israel’s Can-Fite BioPharma has reported success in the Phase I/II clinical trial of its CF102 (Namodenoson) treatment for liver cancer (hepatocellular carcinoma or HCC). It was also successful in Phase I/II trials for treating Hepatitis C. http://www.globes.co.il/serveen/globes/docview.asp?did=1000712199&fid=1725